Sunday, 03 July 2022 06:05 GMT


(MENAFN- PR Newswire)

CAMBRIDGE, Mass., June 23, 2022 /PRNewswire/ -- Proof Diagnostics, Inc. , a healthcare technology company focused on delivering innovative solutions in molecular diagnostics, today announced it has appointed Adam Henry as Senior Vice President of Corporate Development. Mr. Henry brings over 25 years of experience to the company, several of which were spent working directly with startups aiming to disrupt the diagnostics space. He will spearhead the company's overarching growth and business development strategy, reporting directly to CEO and co-founder, Sid Shenai.

Adam Henry, Proof Diagnostics

'Adam's impressive track record of success in leading corporate strategy, business development and strategic marketing functional areas for health tech companies, combined with his passion for diagnostics innovation, makes him uniquely qualified to drive forth our corporate development initiatives,' said Shenai. 'We're a very mission-driven company, so it's critical that our leadership team truly believes in our ability to transform the way we approach personal health by delivering actionable insights at the point-of-care. Adam absolutely shares that belief and we're confident in his ability to build upon our early success and accelerate our company's growth even further.'

Prior to joining Proof Diagnostics, Mr. Henry served as Head of Corporate Strategy and Business Development at Roche-subsidiary GenMark Dx. While at GenMark, he developed, implemented, and actively managed the company's business development initiatives and corporate strategic planning process to inform and drive the long-term vision, direction, and new growth prospects for the company. Before Roche, he served on the Corporate Strategy team at Siemens Healthineers, where he focused on internal management consulting for the company's Diagnostics division, working across the Lab Diagnostics, Molecular Diagnostics, and Point-of-Care business segments. Prior to Siemens, Adam spent several years at Hologic and Gen-Probe (acquired by Hologic) serving in senior management roles responsible for corporate strategy, business development, and strategic/upstream marketing.

'What Proof has been able to accomplish with regards to developing and submitting an entirely new COVID-19 testing system for Emergency Use Authorization in just two years is incredibly impressive,' said Mr. Henry. 'The innovation behind Proof's molecular CRISPR-based technology will help individuals finally get the actionable health insights they need to improve their daily lives, so I'm really excited to help bring these important solutions to market.'

For more information on Proof Diagnostics please visit . 

About Proof Diagnostics:

Proof Diagnostics, Inc. has established itself as an innovative healthcare technology company focused on delivering innovative solutions in molecular diagnostics. Proof's mission is to empower the public to take control of, and better understand, their overall health through lab-quality molecular testing, initiating with COVID-19, that is easy to use, accurate and cost-effective. The Proof Lab Test System comprises the Proof Lab Reader, a portable, scalable diagnostic device that utilizes a Proof Lab Test Cartridge and Proof Lab Test Kit to provide lab-quality results and actionable diagnostic information, helping people lead better, healthier lives.

SOURCE Proof Diagnostics


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.